The active ingredient, semaglutide, is a GLP-1 receptor agonist: a medication that engages the receptor for a hormone the digestive system produces around meals, one that influences appetite and blood sugar. Bodi Envi's Personalized Compounded Semaglutide Weight-Management Programs, offered to people in the Atlanta metro, are built around it.
The compounded form is prepared by a licensed compounding pharmacy for one named patient, on the strength of that patient's prescription. Dosing follows a plan the licensed provider set: a weekly injection, beginning at the dose the provider chooses and changing only when the provider decides it should.
Compounded medications sit outside FDA approval. Personalized Compounded Semaglutide is not FDA-approved, is not equivalent to Ozempic® and Wegovy®, and is not reviewed by the FDA for safety, effectiveness or quality before it is marketed. That is why each prescription rests on a licensed provider's individual judgement. Brand names are trademarks of their respective owners. Compounding pharmacies are regulated by state boards of pharmacy for sterile compounding and are required to follow United States Pharmacopeia standards.